<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">

  <!-- PACE Progress Bar START -->
  
    
<script src="https://raw.githubusercontent.com/HubSpot/pace/v1.0.2/pace.min.js"></script>

    
<link rel="stylesheet" href="https://github.com/HubSpot/pace/raw/master/themes/orange/pace-theme-flash.css">

  
  

  <!-- PACE Progress Bar START -->

  
  <title>Yujie&#39;s Blog</title>
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
  
  
  
  
  <meta name="description" content="How vaccines are made, and why it is hard疫苗是如何制造的，为什么很难 Vaccine manufacture疫苗生产 ![image-20210213104348850](&#x2F;Users&#x2F;chenyujie&#x2F;Library&#x2F;Application Support&#x2F;typora-user-images&amp;#x2F">
<meta property="og:type" content="article">
<meta property="og:title" content="Yujie&#39;s Blog">
<meta property="og:url" content="http://example.com/2021/02/13/Day298-The%20Economist/index.html">
<meta property="og:site_name" content="Yujie&#39;s Blog">
<meta property="og:description" content="How vaccines are made, and why it is hard疫苗是如何制造的，为什么很难 Vaccine manufacture疫苗生产 ![image-20210213104348850](&#x2F;Users&#x2F;chenyujie&#x2F;Library&#x2F;Application Support&#x2F;typora-user-images&amp;#x2F">
<meta property="og:locale">
<meta property="article:published_time" content="2021-02-13T02:42:56.153Z">
<meta property="article:modified_time" content="2021-02-13T02:43:56.774Z">
<meta property="article:author" content="Chen Yujie">
<meta name="twitter:card" content="summary">
  
    <link rel="alternate" href="/atom.xml" title="Yujie&#39;s Blog" type="application/atom+xml">
  
  <link rel="icon" href="/css/images/favicon.ico">
  
    <link href="//fonts.googleapis.com/css?family=Source+Code+Pro" rel="stylesheet" type="text/css">
  
  <link href="https://fonts.googleapis.com/css?family=Open+Sans|Montserrat:700" rel="stylesheet" type="text/css">
  <link href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic" rel="stylesheet" type="text/css">
  <link href="https://cdn.bootcss.com/font-awesome/4.6.3/css/font-awesome.min.css" rel="stylesheet">
  <style type="text/css">
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/9749f0/00000000000000000001008f/27/l?subset_id=2&fvd=n5) format("woff2");font-weight:500;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/90cf9f/000000000000000000010091/27/l?subset_id=2&fvd=n7) format("woff2");font-weight:500;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/8a5494/000000000000000000013365/27/l?subset_id=2&fvd=n4) format("woff2");font-weight:lighter;font-style:normal;}
    @font-face{font-family:futura-pt;src:url(https://use.typekit.net/af/d337d8/000000000000000000010095/27/l?subset_id=2&fvd=i4) format("woff2");font-weight:400;font-style:italic;}</style>
    
  <link rel="stylesheet" id="athemes-headings-fonts-css" href="//fonts.googleapis.com/css?family=Yanone+Kaffeesatz%3A200%2C300%2C400%2C700&amp;ver=4.6.1" type="text/css" media="all">
  
<link rel="stylesheet" href="/css/style.css">


  
<script src="https://code.jquery.com/jquery-3.1.1.min.js"></script>


  <!-- Bootstrap core CSS -->
  <link rel="stylesheet" href="https://netdna.bootstrapcdn.com/bootstrap/3.0.2/css/bootstrap.min.css" >
  <link rel="stylesheet" href="/css/hiero.css" >
  <link rel="stylesheet" href="/css/glyphs.css" >
  
    <link rel="stylesheet" href="/css/vdonate.css" >
  

  <!-- Custom CSS -->
  
<link rel="stylesheet" href="/css/my.css">

  <!-- Google Adsense -->
  
  <script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
  <script>
      (adsbygoogle = window.adsbygoogle || []).push({
          google_ad_client: "ca-pub-0123456789ABCDEF",
          enable_page_level_ads: true
      });
  </script>
  
<meta name="generator" content="Hexo 6.3.0"></head>

<script>
var themeMenus = {};

  themeMenus["/"] = "Home"; 

  themeMenus["/archives"] = "Archives"; 

  themeMenus["/categories"] = "Categories"; 

  themeMenus["/tags"] = "Tags"; 

  themeMenus["/about"] = "About"; 

</script>


  <body data-spy="scroll" data-target="#toc" data-offset="50">


  <header id="allheader" class="site-header" role="banner">
  <div class="clearfix container">
      <div class="site-branding">

          <h1 class="site-title">
            
              <a href="/" title="Yujie&#39;s Blog" rel="home"> Yujie&#39;s Blog </a>
            
          </h1>

          
            <div class="site-description">Welcome to my channel</div>
          
            
          <nav id="main-navigation" class="main-navigation" role="navigation">
            <a class="nav-open">Menu</a>
            <a class="nav-close">Close</a>
            <div class="clearfix sf-menu">

              <ul id="main-nav" class="nmenu sf-js-enabled">
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/">Home</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/archives">Archives</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/categories">Categories</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/tags">Tags</a> </li>
                    
                      <li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1663"> <a class="" href="/about">About</a> </li>
                    
              </ul>
            </div>
          </nav>


      </div>
  </div>
</header>


  <div id="originBgDiv" style="background: #fff; width: 100%;">

      <div style="max-height:600px; overflow: hidden;  display: flex; display: -webkit-flex; align-items: center;">
        <img id="originBg" width="100%" alt="" src="">
      </div>

  </div>

  <script>
  function setAboutIMG(){
      var imgUrls = "css/images/pose.jpg,https://source.unsplash.com/collection/954550/1920x1080".split(",");
      var random = Math.floor((Math.random() * imgUrls.length ));
      if (imgUrls[random].startsWith('http') || imgUrls[random].indexOf('://') >= 0) {
        document.getElementById("originBg").src=imgUrls[random];
      } else {
        document.getElementById("originBg").src='/' + imgUrls[random];
      }
  }
  bgDiv=document.getElementById("originBgDiv");
  if(location.pathname.match('about')){
    setAboutIMG();
    bgDiv.style.display='block';
  }else{
    bgDiv.style.display='none';
  }
  </script>



  <div id="container">
    <div id="wrap">
            
      <div id="content" class="outer">
        
          <section id="main" style="float:none;"><article id="post-Day298-The Economist" style="width: 66%; float:left;" class="article article-type-post" itemscope itemprop="blogPost" >
  <div id="articleInner" class="clearfix post-1016 post type-post status-publish format-standard has-post-thumbnail hentry category-template-2 category-uncategorized tag-codex tag-edge-case tag-featured-image tag-image tag-template">
    
    
    <div class="article-meta">
      
	Posted on <a href="/2021/02/13/Day298-The%20Economist/" class="article-date">
	  <time datetime="2021-02-13T02:42:56.153Z" itemprop="datePublished">February 13, 2021</time>
	</a>

      
	<span id="busuanzi_container_page_pv">
	  本文总阅读量<span id="busuanzi_value_page_pv"></span>次
	</span>

    </div>
    <div class="article-entry" itemprop="articleBody">
      
        <h1 id="How-vaccines-are-made-and-why-it-is-hard"><a href="#How-vaccines-are-made-and-why-it-is-hard" class="headerlink" title="How vaccines are made, and why it is hard"></a>How vaccines are made, and why it is hard</h1><p>疫苗是如何制造的，为什么很难</p>
<h6 id="Vaccine-manufacture"><a href="#Vaccine-manufacture" class="headerlink" title="Vaccine manufacture"></a>Vaccine manufacture</h6><p>疫苗生产</p>
<p>![image-20210213104348850](&#x2F;Users&#x2F;chenyujie&#x2F;Library&#x2F;Application Support&#x2F;typora-user-images&#x2F;image-20210213104348850.png) </p>
<h5 id="Doing-the-do"><a href="#Doing-the-do" class="headerlink" title="Doing the do"></a>Doing the do</h5><p>做那件事</p>
<blockquote>
<p>Feb 6th 2021 </p>
</blockquote>
<p>NINE VACCINES against covid-19 have already been approved in one jurisdiction or another, <strong>with many more in various stages of preparation</strong>. That this has happened within <em>a year</em> <strong>of the illness coming to the world’s attention is remarkable</strong>. <strong>But it is one thing to</strong> design and test vaccines. <strong>It is another to</strong> make them <strong>at sufficient scale</strong> to generate the billions of doses <strong>needed to vaccinate the world’s population</strong>, <strong>and to do so</strong> at such speed that the rate of inoculation can outpace the spread and possible mutation of the virus.</p>
<blockquote>
<p>jurisdiction 管辖区域</p>
</blockquote>
<p>九种新型冠状病毒疫苗已经在一个或另一个司法管辖区获得批准，还有更多疫苗正在不同的准备阶段。这种情况发生在该病引起全世界关注的一年内，这是值得注意的。但是设计和测试疫苗是一回事。另一回事是，在足够大的规模上制造疫苗，以生产为世界人口接种疫苗所需的数十亿剂，而且速度要快到疫苗接种的速度可以超过病毒传播和可能的变异的速度。</p>
<p><strong>Broadly, there are two ways of making antiviral vaccines. One</strong>, <strong>tried and trusted</strong>, <strong>involves growing</strong>, in tanks called bioreactors, <strong>cell cultures</strong> that act as hosts for viruses which are then used <strong>in one way or another</strong> to make the vaccine in question. <strong>Cells</strong> grown this way can be of many types—insect, human kidney, monkey kidney, hamster ovary—<strong>as can the resulting vaccines</strong>. These may be weakened or killed versions of <strong>the virus to be protected against</strong>, <strong>or live viruses</strong> of a different and less-dangerous sort that carry a gene or two abstracted from the target virus, <strong>or even just isolated target-viral proteins</strong>. <strong>The point is that</strong> the vaccine should introduce into the body, <strong>or induce</strong> that body to make, something which the immune system can learn to recognise and attack if the real target virus should ever turn up.</p>
<blockquote>
<p>tried and tested&#x2F;trusted 经过考验的；证明了的；屡试不爽的</p>
<p>tank 容器</p>
<p>ovary 卵巢</p>
<p>turn up 到来</p>
</blockquote>
<p>大体上，有两种方法来制造抗病毒疫苗。一种经过考验的方法是在被称为生物反应器的容器中培养细胞培养物，这些细胞培养物作为病毒的宿主，然后以某种方式用于制造所讨论的疫苗。以这种方式培养的细胞可以是多种类型的——昆虫、人类肾脏、猴子肾脏、仓鼠卵巢——由此产生的疫苗也可以有多种类型。这些病毒可能是被削弱或杀死的可以抵御的病毒，也可能是携带一两个从目标病毒中提取出来的基因的另一种不那么危险的活病毒，甚至可能只是分离出来的靶病毒蛋白。关键在于，疫苗应该引入人体，或诱导人体制造某种物质，以便在真正的目标病毒出现时，免疫系统能够学会识别和攻击这种物质。</p>
<p>In with the new</p>
<p><strong>The alternative method</strong>, developed recently and employed to make the mRNA vaccines, such as those of Moderna and Pfizer, that the pandemic has stimulated the invention of, <strong>requires culturing cells only at the beginning of the process</strong>. mRNA is the substance that carries <strong>instructions</strong> about how to make a protein <strong>from</strong> a cell’s DNA <strong>to</strong> the molecular factories, known as ribosomes, <strong>which do the actual manufacturing</strong>. In the case of covid-19, the instructions <strong>in question</strong> generate spike, a protein found on the surfaces of particles of SARS-CoV-2, the virus that causes this illness. <strong>Suitably packaged and delivered</strong>, such mRNA can induce some of the body cells of the inoculee to <strong>turn out</strong> spike, which the immune system then learns to recognise. To make this type of vaccine you therefore have to generate lots of the relevant mRNA.</p>
<p>另一种方法是最近开发出来的，用于制造mRNA疫苗，如Moderna和辉瑞公司(Pfizer)的疫苗，正是大流行激发了它们的发明，只需要在这个过程的开始阶段培养细胞。信使RNA是一种物质，它携带着如何从细胞的DNA传递给被称为核糖体的分子工厂以制造蛋白质的指令，而核糖体则负责实际制造蛋白质。在covid-19的情况下，所讨论的指令会产生刺突，这是一种在导致该疾病的SARS-CoV-2病毒颗粒表面发现的蛋白质。这样的mRNA经过适当的包装和传递，可以诱导接种体的一些体细胞产生刺突，然后免疫系统学会识别它。因此，为了制造这种疫苗，你必须产生大量相关的mRNA。</p>
<p>That process does indeed start with cells, though they are bacterial cells, rather than those of animals. <strong>But it does not end with them</strong>. The bacteria used, <strong>normally a well-understood species</strong> called E coli, have spliced into them a DNA version of the part of the SARS-CoV-2 genome which describes spike. (Confusingly, as is true of many viruses, SARS-CoV-2’s actual genes are made of RNA.) The bacteria are then allowed to multiply for a few days before being broken open, their DNA filtered out, and the DNA versions of the spike gene extracted <strong>as what is known as</strong> a DNA template.</p>
<p>这个过程确实是从细胞开始的，尽管它们是细菌细胞，而不是动物细胞。但这一切不会就此结束。使用的细菌通常是一种为人熟知的大肠杆菌，它将SARS-CoV-2基因组中描述刺突部分的DNA片段拼接在一起。(令人困惑的是，就像许多病毒一样，SARS-CoV-2的实际基因是由RNA构成的。)然后让细菌繁殖几天，然后被打开，它们的DNA被过滤掉，刺突基因的DNA版本被提取出来，这就是所谓的DNA模板。</p>
<p>Once purified, this template is <strong>mixed with</strong> a soup of pertinent enzymes and fed molecules called nucleotides, the chemical “letters” of which RNA is composed. Thus supplied, the enzymes use the templates to <strong>run off</strong> appropriate mRNAs by the zillion. These are extracted and packaged into tiny, fatty bubbles to form the vaccine.</p>
<blockquote>
<p>zillion 不计其数的</p>
</blockquote>
<p>一旦纯化，这个模板就会与相关酶混合，并注入一种叫做核苷酸(RNA由化学“字母”构成)的分子。这样一来，酶就可以利用模板排出大量合适的信使RNA。这些物质被提取出来，包装成微小的脂肪泡，形成疫苗。</p>
<p><strong>Both</strong> the cell-culture and the mRNA <strong>approaches have benefits and drawbacks.</strong> The former has <strong>the advantage of being well established</strong>. Versions of it <strong>go back to</strong> vaccine-making’s origins. <strong>But keeping</strong> cultured animal cells alive and healthy <strong>is a tricky business</strong>. <strong>A whole subfield of bioengineering is dedicated to this task.</strong> Vaccine-makers who rely on live cultures constantly struggle with yields**. Using this method to make a lot of vaccine, fast, is hard**.</p>
<p>细胞培养法和mRNA方法各有优缺点。前者的优点是成熟。它的版本可以追溯到疫苗制造的起源。但是保持培养的动物细胞的存活和健康是一件棘手的事情。生物工程的整个分支领域都致力于这项任务。依赖活菌培养的疫苗制造商一直在努力提高产量。用这种方法快速生产大量疫苗是困难的。</p>
<p><strong>It was difficulties of this sort</strong> that Pascal Soriot, boss of AstraZeneca, cited on January 26th <strong>in defence of</strong> his firm’s failure to provide vaccine supplies which the European Union claimed it had been promised. AstraZeneca is an Anglo-Swedish company that, <strong>in collaboration with</strong> Oxford University, created <strong>one of the first</strong> vaccines to be approved. As Mr Soriot told La Repubblica, an Italian newspaper, “You have glitches, you have scale-up problems. The best site we have produces three times more vaccine out of a batch than the lowest-producing site.”</p>
<p>1月26日，阿斯利康公司老板帕斯卡尔•索里奥(Pascal Soriot)在为自己的公司未能提供承诺欧盟的疫苗供应辩护时，引用的正是这类困难，阿斯利康(AstraZeneca)是一家英瑞合资公司，它与牛津大学(Oxford University)合作，研制出了首批获批的疫苗之一。正如索里奥对意大利报纸《共和报》(La Repubblica)所言，“你有小差错，你有扩大规模的问题。”我们最好的生产基地每批生产的疫苗是最低生产基地的三倍。”</p>
<p>De-necking the bottles</p>
<p><strong>Maximising a bioreactor’s yield is as much an art as a science. The underlying health of the cells involved matters. So do environmental conditions at the manufacturing site.</strong> That AstraZeneca has not been able to meet its own production targets <strong>shows</strong> how hard it is to predict when the right balance of biology will be found. The company says it can take six to nine months to start a production site <strong>up from scratch</strong>, <strong>and that even this timetable is possible only by</strong> working with experienced partners <strong>and at an accelerated pace</strong>. <strong>At the moment</strong>, AstraZeneca is working with 25 manufacturing organisations in 15 countries to make its vaccine.</p>
<p>最大限度地提高生物反应器的产量既是一门艺术，也是一门科学。细胞的潜在健康也牵涉其中。生产现场的环境条件也是如此。阿斯利康未能达到自己的生产目标表明，预测何时能找到合适的生物平衡是多么困难。该公司表示，从头开始建设一个生产基地可能需要6到9个月的时间，而且只有通过与经验丰富的合作伙伴合作并加快速度，才有可能实现这个时间表。目前，阿斯利康正在与15个国家的25个生产组织合作生产疫苗。</p>
<p><strong>Producing mRNA vaccines at scale has problems, too. The biggest is</strong> how to <strong>protect</strong> the mRNA molecules <strong>both from</strong> the environment they must travel through in order to reach the arm of their recipient, <strong>and from</strong> the recipient’s own body, which will attack them as they journey to the ribosomes which will transcribe them.</p>
<p>大规模生产mRNA疫苗也存在问题。最大的问题是如何保护mRNA分子，既不受环境的影响（它们必须通过环境才能到达受体的手臂），也不受受体自身的影响（因为它们到达会转录它们的核糖体时会受到攻击）。</p>
<p>Protection from the environment is mainly <strong>a matter of</strong> having a strategically located set of refrigerators, known as a <strong>cold chain</strong>. Protection from the body, though, is where the fatty bubbles <strong>come in</strong>.</p>
<blockquote>
<p>come in 起作用</p>
</blockquote>
<p>免受环境的影响主要是在战略位置上有一套冰箱，被称为冷链。不过，脂肪泡泡的作用就在于免受受体自身的影响。</p>
<p>Production of these bubbles was a cottage industry before the pandemic. A small Austrian firm, Polymun Scientific, is <strong>one of just a handful that can make them</strong>. Their main previous use was in niche cancer treatments. Scaling up their production, which is happening right now, has never been done before and <strong>adds uncertainty to</strong> the continued supply of mRNA vaccine.</p>
<p>在大流行之前，这些脂肪泡的生产是一个家庭手工业。一家奥地利的小公司，Polymun Scientific，是为数不多的几个能够制造它们的公司之一。它们之前主要用于小众癌症治疗。目前正在进行的扩大它们的生产规模，是以前从未做过的，这给持续供应mRNA疫苗增加了不确定性。</p>
<p><strong>There are other bottlenecks, too. In particular,</strong> the factories <strong>in which vaccines are made</strong> must be built to a high standard, known as GMP, for “Good Manufacturing Practice”. <strong>There is currently a shortage of GMP facilities.</strong> Andrey Zarur, boss of GreenLight Biosciences, a firm in Boston that is developing an mRNA vaccine, says his company has employees whose entire job, at present, is to <strong>work the phones</strong> trying to find GMP facilities in which to make their vaccine. <strong>There is, though, nothing available.</strong> He is therefore looking to buy firms whose vaccine candidates have turned out not to work, simply in order to acquire the facilities in question.</p>
<p>还有其他瓶颈。特别是，生产疫苗的工厂必须按照高标准建造，即所谓的GMP，即“良好生产规范”。目前GMP设备短缺。GreenLight Biosciences是一家位于波士顿的公司，正在研发一种mRNA疫苗。该公司的老板安德烈·扎鲁尔(Andrey Zarur)说，他公司的员工目前的全部工作就是打电话，试图找到生产疫苗的GMP设施。但是，没有可用的。因此，他正在寻求收购那些候选疫苗结果无效的公司，仅仅是为了获得有关设施。</p>
<p><strong>Supplies of raw materials</strong> such as nucleotides <strong>are also tight</strong>. According to Dr Zarur, Thermo Fisher, an American chemical-supplies company, has spent $200m on a new facility in Lithuania to make these molecules, though the firm itself would not confirm this.</p>
<p>核苷酸等原材料的供应也很紧张。据扎鲁尔博士说，美国化学用品公司Thermo Fisher已经在立陶宛投资了2亿美元，在一个新的设施上制造这些分子，不过该公司自己不愿证实这一点。</p>
<p><strong>On top of all this</strong>, <strong>the transport and distribution of vaccines once they have been made presents yet further challenges, and concomitant potential for hold ups</strong>. Vaccines must be stored in special non-reactive glass vials. <strong>Some</strong>, such as the current version of Pfizer’s mRNA vaccine, <strong>must also be kept at extremely low temperatures</strong>, <strong>though that problem may go away soon</strong>. Drew Weissman, one of the inventors of mRNA-vaccine technology, says producers are now testing shots which are stable for three months when kept at 4°C.</p>
<blockquote>
<p>concomitant 伴随的</p>
<p>hold up 延误</p>
<p>vial 小瓶</p>
<p>go away 消失</p>
</blockquote>
<p>除此之外，疫苗一旦生产出来，运输和分发就会带来进一步的挑战，并有可能造成拖延。疫苗必须储存在特殊的非反应性玻璃瓶中。有些疫苗，比如辉瑞公司目前的mRNA疫苗，也必须在极低的温度下保存，尽管这个问题可能很快就会解决。信使RNA疫苗技术的发明者之一德鲁·韦斯曼(Drew Weissman)表示，生产商目前正在测试在4°C下可以稳定接种3个月的疫苗。</p>
<p><strong>Once supply chains</strong> for both cell-culture and mRNA vaccines <strong>have been scaled up</strong>, <strong>and bottlenecks unblocked, the manufacturing processes may face a different test</strong>—how quickly they can produce new vaccines to deal with new viral variants as these emerge. The continued efficacy of approved vaccines against such variants is not guaranteed, and it may be necessary to make others.</p>
<p>一旦细胞培养疫苗和mRNA疫苗的供应链规模扩大，瓶颈解除，生产过程可能面临一个不同的考验, 即它们能以多快的速度生产出新的疫苗，以应对出现的新病毒变体。经批准的疫苗对这类变异的持续有效性无法保证，因此可能有必要制造其他疫苗</p>
<p><strong>Here, the mRNA approach may have an advantage.</strong> Its production systems will require a simple tweak—the dropping in at the start of a DNA template describing the new variant’s spike protein. Cell-culture systems, <strong>by contrast</strong>, will have to be rebuilt <strong>to some degree</strong> for every new variant they aim to vaccinate against.</p>
<p>在这里，信使RNA方法可能有优势。它的生产系统将需要一个简单的调整——在描述新变种的刺突蛋白的DNA模板的开始处插入。相比之下，细胞培养系统必须在一定程度上重建，以应对每一种新的病毒变体。</p>
<p>Scale models</p>
<p>Producers, such as those in China, who use older-fashioned cell-culture techniques, will have to recalibrate their entire operations. Newer systems, like AstraZeneca’s, which use cells specially designed so as not to <strong>be influenced by</strong> the new version of the spike gene in the viruses they are carrying, should be able to <strong>get on track</strong> in the time it takes to start a culture <strong>from scratch</strong>—about a month. For mRNA systems, Drs Weissman and Zarur say it would take a couple of months to go from new variant to large-scale vaccine production. If variants <strong>resistant to</strong> the current crop of vaccines do evolve, t<strong>hen that speed and certainty in making new vaccines to combat them will be essential</strong>. ■</p>
<p>使用老式细胞培养技术的生产商，比如中国的生产商，将不得不重新调整他们的整个业务。像阿斯利康（AstraZeneca）这样的新系统，使用专门设计的细胞，以避免受到携带病毒中新版本的spike基因的影响，应该能够在大约一个月的时间内从零开始培养。对于信使RNA系统，韦斯曼博士和扎鲁尔博士说，从新变种到大规模生产疫苗需要几个月的时间。如果对现有疫苗具有抗性的变种确实在进化，那么制造新疫苗对抗它们的速度和确定性将是至关重要的。■</p>

      
    </div>
    <footer class="entry-meta entry-footer">
      
      
      
        <div id="donation_div"></div>


<script src="/js/vdonate.js"></script>

<script>
var a = new Donate({
  title: '如果觉得我的文章对您有用，请随意打赏。您的支持将鼓励我继续创作!', // 可选参数，打赏标题
  btnText: 'Donate', // 可选参数，打赏按钮文字
  el: document.getElementById('donation_div'),
  wechatImage: 'https://raw.githubusercontent.com/iTimeTraveler/iTimeTraveler.github.io/site/source/about/donate/images/WeChanQR.png',
  alipayImage: 'https://raw.githubusercontent.com/iTimeTraveler/iTimeTraveler.github.io/site/source/about/donate/images/AliPayQR.jpg'
});
</script>
      
            
      
        
	<div id="comment">
		<!-- 来必力City版安装代码 -->
		<div id="lv-container" data-id="city" data-uid="MTAyMC8yOTQ4MS82MDQ5">
		<script type="text/javascript">
		   (function(d, s) {
		       var j, e = d.getElementsByTagName(s)[0];

		       if (typeof LivereTower === 'function') { return; }

		       j = d.createElement(s);
		       j.src = 'https://cdn-city.livere.com/js/embed.dist.js';
		       j.async = true;

		       e.parentNode.insertBefore(j, e);
		   })(document, 'script');
		</script>
		<noscript>为正常使用来必力评论功能请激活JavaScript</noscript>
		</div>
		<!-- City版安装代码已完成 -->
	</div>


      
    </footer>
  </div>
  
    
<nav id="article-nav">
  
    <a href="/2021/02/14/Day299-The%20Economist/" id="article-nav-newer" class="article-nav-link-wrap">
      <strong class="article-nav-caption">Newer</strong>
      <div class="article-nav-title">
        
          (no title)
        
      </div>
    </a>
  
  
    <a href="/2021/02/12/Day297-The%20Economist/" id="article-nav-older" class="article-nav-link-wrap">
      <strong class="article-nav-caption">Older</strong>
      <div class="article-nav-title"></div>
    </a>
  
</nav>

  
</article>

<!-- Table of Contents -->

  <aside id="sidebar">
    <div id="toc" class="toc-article" style="overflow-y: scroll; max-width: 28%;">
    <strong class="toc-title">Contents</strong>
    
      <ol class="nav"><li class="nav-item nav-level-1"><a class="nav-link" href="#How-vaccines-are-made-and-why-it-is-hard"><span class="nav-number">1.</span> <span class="nav-text">How vaccines are made, and why it is hard</span></a><ol class="nav-child"><li class="nav-item nav-level-6"><a class="nav-link" href="#Vaccine-manufacture"><span class="nav-number">1.0.0.0.0.1.</span> <span class="nav-text">Vaccine manufacture</span></a></li></ol></li><li class="nav-item nav-level-5"><a class="nav-link" href="#Doing-the-do"><span class="nav-number">1.0.0.0.1.</span> <span class="nav-text">Doing the do</span></a></li></ol></li></ol></li></ol></li></ol></li></ol>
    
    </div>
  </aside>
</section>
        
      </div>
      <footer id="footer" class="site-footer">
  

  <div class="clearfix container">
      <div class="site-info">
	      &copy; 2023 Yujie&#39;s Blog All Rights Reserved.
          
            <span id="busuanzi_container_site_uv">
              本站访客数<span id="busuanzi_value_site_uv"></span>人次  
              本站总访问量<span id="busuanzi_value_site_pv"></span>次
            </span>
          
      </div>
      <div class="site-credit">
        Theme by <a href="https://github.com/iTimeTraveler/hexo-theme-hiero" target="_blank">hiero</a>
      </div>
  </div>
</footer>


<!-- min height -->

<script>
    var contentdiv = document.getElementById("content");

    contentdiv.style.minHeight = document.body.offsetHeight - document.getElementById("allheader").offsetHeight - document.getElementById("footer").offsetHeight + "px";
</script>

<!-- Custome JS -->

<script src="/js/my.js"></script>

    </div>
    <!-- <nav id="mobile-nav">
  
    <a href="/" class="mobile-nav-link">Home</a>
  
    <a href="/archives" class="mobile-nav-link">Archives</a>
  
    <a href="/categories" class="mobile-nav-link">Categories</a>
  
    <a href="/tags" class="mobile-nav-link">Tags</a>
  
    <a href="/about" class="mobile-nav-link">About</a>
  
</nav> -->
    

<!-- mathjax config similar to math.stackexchange -->

<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    tex2jax: {
      inlineMath: [ ['$','$'], ["\\(","\\)"] ],
      processEscapes: true
    }
  });
</script>

<script type="text/x-mathjax-config">
    MathJax.Hub.Config({
      tex2jax: {
        skipTags: ['script', 'noscript', 'style', 'textarea', 'pre', 'code']
      }
    });
</script>

<script type="text/x-mathjax-config">
    MathJax.Hub.Queue(function() {
        var all = MathJax.Hub.getAllJax(), i;
        for(i=0; i < all.length; i += 1) {
            all[i].SourceElement().parentNode.className += ' has-jax';
        }
    });
</script>

<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.4/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
</script>



  
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/2.1.5/jquery.fancybox.min.css">

  
<script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/2.1.5/jquery.fancybox.min.js"></script>




<script src="/js/scripts.js"></script>


<script src="https://stackpath.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>


<script src="/js/main.js"></script>








  <div style="display: none;">
    <script src="https://s95.cnzz.com/z_stat.php?id=1260716016&web_id=1260716016" language="JavaScript"></script>
  </div>



	<script async src="https://dnqof95d40fo6.cloudfront.net/atw7f8.js">
	</script>






  </div>

  <a id="rocket" href="#top" class=""></a>
  <script type="text/javascript" src="/js/totop.js" async=""></script>
</body>
</html>
